Get started
Author

Clarisse Audigier-Valette

Observed names: Audigier-Valette, Clarisse, C Audigier Valette, C Audigier-Valette, C VALETTE, C Valette, C. Audigier Valette, C. Audigier-Valette, C.A. Valette, Clarisse Audigier Valette, Clarisse Audigier-valette, Clarisse Audigier‐Valette
Observed institutions: Memorial Sloan Kettering Cancer Center, Iuliu Hațieganu University of Medicine and Pharmacy, Aix-Marseille Université, Institut Gustave Roussy, Seoul National University Bundang Hospital, Assistance Publique Hôpitaux de Marseille, Assistance Publique – Hôpitaux de Paris, Intergroupe Francophone de Cancérologie Thoracique, Hospices Civils de Lyon, Institute of Oncology Prof. Dr. Ion Chiricuta, Centre Hospitalier Universitaire d'Angers, Hôpital Edouard Herriot, Hôpital Larrey, Centre Hospitalier Universitaire de Clermont-Ferrand, Centre de Recherche en Cancérologie de Marseille, Institut Paoli-Calmettes, Centre Hospitalier Intercommunal Toulon-La Seyne-sur-Mer, Centre Hospitalier Universitaire de Rennes, Hôpital Tenon, The Ohio State University
ORCID: 0000-0002-9518-9162
Observed ORCID: 0000-0002-9518-9162
OpenAlex ID: A5002994604
Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden
2018 · Matthew D. Hellmann, Tudor-Eliade Ciuleanu, et al. · New England Journal of Medicine · 3,106
PDF
Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT)
2016 · Fabrice Barlesi, Julien Mazieres, et al. · The Lancet · 1,045
PDF
Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial
2015 · Gérard Zalcman, Julien Mazieres, et al. · The Lancet · 997
Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non–Small Cell Lung Cancer
2018 · Laura Mezquita, Edouard Auclin, et al. · JAMA Oncology · 945
PDF
Hyperprogressive Disease in Patients With Advanced Non–Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy
2018 · Roberto Ferrara, Laura Mezquita, et al. · JAMA Oncology · 745
PDF
Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer
2022 · Lisa Derosa, Bertrand Routy, et al. · Nature Medicine · 728
Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial
2019 · Arnaud Scherpereel, Julien Mazieres, et al. · The Lancet Oncology · 476
PDF
Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non–Small-Cell Lung Cancer in CheckMate 227
2022 · Julie R. Brahmer, Jong-Seok Lee, et al. · Journal of Clinical Oncology · 459
PDF
Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients
2017 · Myriam Delaunay, Jacques Cadranel, et al. · European Respiratory Journal · 427
PDF
Use of a Comprehensive Geriatric Assessment for the Management of Elderly Patients With Advanced Non–Small-Cell Lung Cancer: The Phase III Randomized ESOGIA-GFPC-GECP 08-02 Study
2016 · Romain Corre, Laurent Greillier, et al. · Journal of Clinical Oncology · 411
First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial
2021 · Luis G. Paz-Ares, Suresh S. Ramalingam, et al. · Journal of Thoracic Oncology · 339
Second-line nivolumab in relapsed small-cell lung cancer: CheckMate 331☆
2021 · D.R. Spigel, D. Vicente, et al. · Annals of Oncology · 276
Outcome of Patients with Non–Small Cell Lung Cancer and Brain Metastases Treated with Checkpoint Inhibitors
2019 · Lizza E.L. Hendriks, Clemence Henon, et al. · Journal of Thoracic Oncology · 242
PDF
Custom scoring based on ecological topology of gut microbiota associated with cancer immunotherapy outcome
2024 · Lisa Derosa, Valerio Iebba, et al. · Cell · 224
A Randomized Non-Comparative Phase II Study of Anti-Programmed Cell Death-Ligand 1 Atezolizumab or Chemotherapy as Second-Line Therapy in Patients With Small Cell Lung Cancer: Results From the IFCT-1603 Trial
2019 · Jean-Louis Pujol, Laurent Greillier, et al. · Journal of Thoracic Oncology · 184
PDF
Sacituzumab Govitecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III EVOKE-01 Study
2024 · Luis G. Paz-Ares, Oscar Juan-Vidal, et al. · Journal of Clinical Oncology · 167
PDF
Overall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective study
2017 · Michaël Duruisseaux, Benjamin Besse, et al. · Oncotarget · 164
PDF
Efficacy of Immune Checkpoint Inhibitors in Lung Sarcomatoid Carcinoma
2020 · Charlotte Domblides, Karen Leroy, et al. · Journal of Thoracic Oncology · 140
PDF
Epidemiology and Treatment Costs of Bone Metastases from Lung Cancer: A French Prospective, Observational, Multicenter Study (GFPC 0601)
2011 · Chantal Decroisette, Isabelle Monnet, et al. · Journal of Thoracic Oncology · 137
Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy – results from the randomised phase II ETOP/IFCT 4-12 STIMULI trial
2021 · S. Peters, J.-L. Pujol, et al. · Annals of Oncology · 136
PDF
On the relevance of a testing algorithm for the detection of ROS1-rearranged lung adenocarcinomas
2013 · Lénaïg Mescam-Mancini, Sylvie Lantuéjoul, et al. · Lung Cancer · 122
PDF
Efficacy and safety of nivolumab (nivo) monotherapy versus chemotherapy (chemo) in recurrent small cell lung cancer (SCLC): Results from CheckMate 331
2018 · M. Reck, D. Vicente, et al. · Annals of Oncology · 105
First-line nivolumab plus ipilimumab for metastatic non-small cell lung cancer, including patients with ECOG performance status 2 and other special populations: CheckMate 817
2023 · Neal E Ready, Clarisse Audigier-Valette, et al. · Journal for ImmunoTherapy of Cancer · 80
PDF
Weekly paclitaxel plus bevacizumab versus docetaxel as second- or third-line treatment in advanced non-squamous non–small-cell lung cancer: Results of the IFCT-1103 ULTIMATE study
2020 · Alexis B. Cortot, Clarisse Audigier-Valette, et al. · European Journal of Cancer · 73
PDF
Nivolumab + ipilimumab versus platinum-doublet chemotherapy as first-line treatment for advanced non-small cell lung cancer: Three-year update from CheckMate 227 Part 1.
2020 · Suresh S. Ramalingam, Tudor Eliade Ciuleanu, et al. · Journal of Clinical Oncology · 72
Works count: 311
Citation count: 14,230
H-index: 42
I10-index: 103
Year
Topic
Type